Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06190886 · ClinicalTrials.gov registry record · Phase 1
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
A Phase 1 study of Solid Tumor and Advanced Cancer, sponsored by Proviva Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 3
- Study locations
NCT06190886: Recruiting Phase 1 study of Solid Tumor and Advanced Cancer, sponsored by Proviva Therapeutics.
NCT06190886 is a Phase 1 study of Solid Tumor and Advanced Cancer that is actively recruiting participants, run by Proviva Therapeutics. The registered enrollment target is 26 participants, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06190886, a Phase 1 study of Solid Tumor and Advanced Cancer, is actively recruiting participants, sponsored by Proviva Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of PTX-912 in patients with locally advanced or metastatic solid tumors. To evaluate the PK and immunogenicity profile of PTX-912. To evaluate the preliminary anti-tumor activity of PTX-912. Participants will be treated with PTX-912 via iv infusion, every 2 weeks until progression of disease, unacceptable toxicity, or 12 months of total study therapy.
Primary Outcome
Frequency, severity, and duration of treatment-emergent adverse events (TEAEs) and laboratory abnormalities for all dose groups according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0; except for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) which will be graded according to American Society for Transplantation and Cellular Therapy (ASTCT) Consensus Grading.
Conditions Studied
Interventions
- DRUG PTX-912
Study Locations (3)
California
- City of Hope National Medical Center - Duarte
Florida
- University of Miami - Miami
Nebraska
- Nebraska Cancer Specialists (NCS) - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2024-06-11 |
| Est. Completion | 2026-07-24 |
| Phase | Phase 1 |
What NCT06190886 shows while recruiting
NCT06190886 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (88% lower).
The record links to 3 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which PTX-912 is the first listed.
NCT06190886 reports a single indexed study location in California, Florida, Nebraska.
Frequently Asked Questions
What is clinical trial NCT06190886 about?
NCT06190886 is a clinical study titled "A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors". The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of PTX-912 in patients with locally advanced or metastatic solid tumors. To evaluate the PK and immunogenicity profile of PTX-912. To evaluate the preliminary anti-tumor activity of PTX-912. Participants ...
What is the current status of trial NCT06190886?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2024-06-11. Estimated completion is 2026-07-24.
What conditions does trial NCT06190886 study?
This clinical trial studies the following conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer.
What interventions are being tested in trial NCT06190886?
The interventions under investigation include: PTX-912 (DRUG).
Who is sponsoring clinical trial NCT06190886?
This trial is sponsored by Proviva Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06190886 being conducted?
This trial has 3 study locations across California, Florida, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06190886's enrollment target sits among peer trials
26 166th of 196 higher than 31 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI